Gene Editing Leader Drops 10% in One Day

Gene-editing therapy developer CRISPR Therapeutics AG (CRSP) plunged 9.84% on the Nasdaq on the 24th, closing at $49.75 (approximately KRW 70,000). Its market capitalization shrank to around $4.8 billion (KRW 6.7 trillion), erasing about $430 million (KRW 600 billion) in a single day. Trading volume reached 2.76 million shares, reflecting both short-term profit-taking and increased volatility.

CRISPR Therapeutics recently released its Q4 2025 and full-year results, providing updates on the commercial launch of its first CRISPR-based therapy, Casgevi, and progress in its in vivo gene-editing pipeline. In March, the company announced plans to issue $350 million (approximately KRW 500 billion) in convertible notes to secure funding for future clinical trials and commercialization.

Based in Switzerland and the United States, CRISPR Therapeutics is a biotech firm using CRISPR-Cas9 gene-editing technology to develop treatments targeting sickle cell disease, beta-thalassemia, cancer, and cardiovascular disorders. Casgevi, a one-time gene therapy co-developed with Vertex Pharmaceuticals and the first CRISPR-based treatment approved by the U.S. FDA in 2023, is considered a key pipeline asset that will determine the company’s mid- to long-term growth potential.